- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 3, 2024Can You Keep a Secret? Privacy Laws and Civil Litigation
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches Q4 2012
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
Reference Listed Drug |
NDA Holder |
Generic Drug Name |
ANDA Applicant(s) |
Indication |
Launch Date |
Cafcit | Bedford Labs | Caffeine Citrate Injection, | Sagent Pharmaceuticals | treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age | 10/3/2012 |
Cafcit | Bedford Labs | Caffeine Citrate Oral Solution, USP | Sagent Pharmaceuticals | treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age | 10/3/2012 |
Evoxac | Daiichi Sankyo | Cevimeline Hydrochloride 30 mg. capsules | Ranbaxy Laboratories | treatment of symptoms of dry mouth associated with Sjogren's Syndrome | 10/9/2012 |
Topicort | Taro Pharms North | Desoximetasone Ointment USP, 0.25% | Sandoz | topical steroid: allergic reactions, eczema, and psoriasis |
10/10/2012 |
Avapro | Sanofi | Irbesartan Tablets | Watson Laboratories | hypertension | 10/12/2012 |
Sanctura XR | Allergan | Trospium Chloride Extended-release Capsules | Watson Pharmaceuticals | overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency | 10/12/2012 |
Avapro | Sanofi Aventis | Irbesartan | Roxane Laboratories | hypertension | 10/15/2012 |
Avalide | Sanofi Aventis | Irbesartan / Hydrochlorothiazide | Roxane Laboratories | hypertension | 10/15/2012 |
Optivar | Meda Pharmaceuticals | Azelastine Ophthalmic Solution | Sandoz | antihistamine: itchy eyes | 10/23/2012 |
Seasonale | Teva Branded Pharmaceuticals | Levonorgestrel and Ethinyl Estradiol Tablets USP 0.15 mg/0.03 mg | Lupin Pharmaceuticals | oral contraceptive | 10/25/2012 |
Actos | Takeda Pharms USA | Pioglitazone Hydrochloride | Watson Pharmaceuticals | type 2 diabetes | 10/26/2012 |
Leucovorin Calcium | Bedford Labs | Leucovorin Calcium for Injection | Sagent Pharmaceuticals | megaloblastic anemias | 10/29/2012 |
Revatio | Pfizer | Sildenafil Tablets | Watson Pharmaceuticals | pulmonary arterial hypertension | 11/12/2012 |
Revatio | Pfizer | Sildenafil Citrate Tablets | Mylan Laboratories | pulmonary arterial hypertension | 11/13/2012 |
Diamox | Teva Women's | Acetazolamide for Injection, USP | Sagent Pharmaceuticals | adjunctive treatment of edema due to congestive heart failure | 11/13/2012 |
Revatio | Pfizer | Sildenafil Citrate Tablets | Dr. Reddy’s Laboratories | pulmonary arterial hypertension |
11/16/2012 |
Tricor | Abbott | Fenofibrate Tablets, 48 mg and 145 mg | Lupin Pharmaceuticals | primary hypercholesterolemia and severe hypertriglyceridemia | 11/20/2012 |
Absorica | Cipher Pharmaceuticals | Isotretinoin | Ranbaxy Laboratories | treatment of severe recalcitrant nodular acne | 11/26/2012 |
Nallpen | Baxter Healthcare | Nafcillin - semisynthetic | Sagent Pharmaceuticals | treatment of infections caused by penicillinase-producing staphylococci | 11/28/2012 |
Detrol | Pharmacia and Upjohn | Tolterodine Tartrate Tablets | Mylan Pharmaceuticals | overactive bladder | 11/29/2012 |
Symbyax | Eli Lilly & Co | Olanzapine / Fluoxetine | Sandoz | depression caused by bipolar disorder |
11/30/2012 |
Atacand HCT | AstraZeneca | Candesartan Cilexetil / Hydrochlorothiazide Tablets | Mylan Pharmaceuticals | hypertension | 12/5/2012 |
Qualaquin | Mutual Pharmaceutical Company | Quinine Sulfate Capsules USP | Mylan Pharmaceuticals | plasmodium falciparum malaria | 12/18/2012 |
Yasmin | Bayer Healthcare | Drospirenone / Ethinyl Estradiol Tablets, 3 mg/0.03 mg | Lupin Pharmaceuticals | oral contraceptive | 12/19/2012 |
Nordette 28 | Teva Branded Pharmaceutical Products | Levonorgestrel / Ethinyl Estradiol Tablets USP | Mylan Inc Partner Famy Care (Distributed in the U.S. by Mylan Pharmaceuticals Inc.) | method of contraception | 12/28/2012 |
Dilantin | Pfizer | Phenytoin Chewable Tablets USP | Mylan Pharmaceuticals | prevention and treatment of seizures occurring during or following neurosurgery | 12/28/2012 |
GENERICally Speaking Winter 2012
Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.